Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
61. |
ECCT/20/08/02 | ALIVE study Evaluation of the effectiveness of IVERMECTIN co-formulation vs ALBENDAZOLE for treatment of for the Treatment of Soil-Transmitted Helminth Infections (Trichuris trichiura, hookworm, Strongyloides stercoralis) in school aged children and Young Adult Subjects (ALIVE Study) |
Principal Investigator(s) 1. Charles Mwandawiro Site(s) in Kenya Kwale |
12-01-2021 |
View |
62. |
ECCT/20/11/01 | GC vaccine study in kenya Protocol Title: USE OF BEXSERO IMMUNIZATION TO DETECT CROSS REACTIVE ANTIGENS AND ANTI-GONOCOCCAL ANTIBODIES IN KEY POPULATIONS IN KENYA. |
Principal Investigator(s) 1. Prof. Eduard Sanders Site(s) in Kenya The KEMRI-Wellcome Trust Research Programme (KWTRP) Kenya Medical Research Institute (KEMRI) / Wellcome Trust Centre for Geographic Medicine Research – Coast (CGMRC) |
10-02-2021 |
View |
63. |
ECCT/20/11/03 | IMR-SCD-301 A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba Site(s) in Kenya 1. Kenya Medical Research Institute-Kondele Children\'s Hospital (Kisumu county) 2. The Center For Respiratory Disease Research/KEMRI (Nairobi City county) 3. Gertrude\'s Children\'s Hospital (Nairobi City county) |
24-02-2021 |
View |
64. |
ECCT/20/11/02 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults (IAVI C100) |
Principal Investigator(s) 1. Nelly Mugo Site(s) in Kenya 1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county) 2. Kenya AIDS Vaccine Initiative- Institute of Clinical Research (KAVI-ICR) (Nairobi City county) |
03-03-2021 |
View |
65. |
ECCT/20/12/03 | CALINA STUDY A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria. Study number: CCOA566B2307 |
Principal Investigator(s) 1. Benhards Ragama Ogutu Site(s) in Kenya KEMRI-Centre for Clinical Research (CCR) |
08-03-2021 |
View |
66. |
ECCT/21/02/04 | GASTROSAM GASTROSAM Gastroenteritis: Rehydration of children with severe acute malnutrition |
Principal Investigator(s) 1. Professor Kathryn Maitland Site(s) in Kenya Kilifi County Hospital |
13-05-2021 |
View |
67. |
ECCT/21/05/03 | Adapt Out COVID Adaptive Platform Treatment trial for Outpatients with COVID-19 |
Principal Investigator(s) 1. Kawango Agot Site(s) in Kenya 1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county) 2. KEMRI WALTER REED (Kericho county) 3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 4. Kenya Medical Research Institute (Kisumu county) |
28-07-2021 |
View |
68. |
ECCT/19/11/01 | A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults. Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults. |
Principal Investigator(s) 1. Melissa Kapulu Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
07-08-2021 |
View |
69. |
ECCT/21/05/06 | VAC52150EBL2010 ;Phase 2 An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen |
Principal Investigator(s) 1. Prof. Omu Anzala Omu Anzala Site(s) in Kenya KAVI-institute of Clinical Research |
11-08-2021 |
View |
70. |
ECCT/21/05/05 | The “EMPATHY†Trial A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19. |
Principal Investigator(s) 1. DR LUCAS OTIENO TINA 2. Dr. Bernhards Ragama Ogutu 3. Dr Deborah Chepngeno Langat 4. Dr Videlis Nduba Nduba 5. Dr Janet Oyieko Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. Kenyatta University Teaching Referral and Research Hospital (KUTRRH) (Nairobi City county) 3. Kenya Medical Research Institute/US Army Medical Research Directorate-Kenya-Kericho (Kericho county) 4. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 5. KEMRI-USAMRD-A, Kisumu Field Station (Kisumu county) |
11-08-2021 |
View |